Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $302,609.07 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 11,881 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $25.47, for a total transaction of $302,609.07. Following the completion of the sale, the chief operating officer owned 377,802 shares in the company, valued at approximately $9,622,616.94. This trade represents a 3.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

• On Friday, October 30th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $26.73, for a total transaction of $317,579.13.
• On Wednesday, October 28th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $28.45, for a total value of $338,014.45.
• On Monday, October 26th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $26.04, for a total value of $309,381.24.
• On Friday, October 23rd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $24.98, for a total value of $296,787.38.
• On Monday, October 19th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $24.05, for a total value of $285,738.05.
• On Wednesday, October 21st, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.41, for a total value of $301,896.21.
• On Thursday, October 15th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.61, for a total value of $304,272.41.
• On Tuesday, October 13th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.50, for a total value of $302,965.50.
• On Thursday, October 8th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.66, for a total value of $304,866.46.
• On Monday, October 5th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $29.19, for a total value of $346,806.39.

Adaptive Biotechnologies Price Performance

Shares of ADPT opened at $26.83 on Friday. Adaptive Biotechnologies Corporation has a 52 week low of $12.00 and a 52 week high of $30.74. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22. The firm has a market cap of $4.28 billion, a price-to-earnings ratio of -59.62 and a beta of 2.18. The stock has a 50 day moving average of $26.39 and a 200-day moving average of $19.81.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.12. Adaptive Biotechnologies had a negative return on equity of 23.47% and a negative net margin of 23.67%. The business had revenue of $83.90 million for the quarter, compared to analyst estimates of $71.57 million. During the same period in the prior year, the company posted $0.06 EPS. The business’s revenue was down 10.7% compared to the same quarter last year. As a group, analysts forecast that Adaptive Biotechnologies Corporation will post -0.40 EPS for the current year.

Trending Headlines about Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Adaptive reported Q3 earnings of $0.02 per share, versus the consensus estimate of a $0.10 loss, and revenue of $83.9 million, above the $71.6 million expected. Management also said the company reached total-company profitability ahead of expectations. Quarterly results
• Positive Sentiment: Core MRD revenue grew 44%, and Adaptive raised its 2026 MRD revenue outlook to $276 million–$286 million. The company also outlined a target average selling price of $1,700–$1,800, signaling confidence in continued growth of this business. MRD outlook
• Neutral Sentiment: COO Julie Rubinstein sold 11,881 shares under a pre-arranged Rule 10b5-1 plan and retained a substantial stake. The planned nature of the sales may make them less informative about her outlook, though insider selling can draw investor attention. Insider sale report
• Negative Sentiment: Despite the quarterly beat, revenue was down 10.7% from a year earlier, and the company continued to report a negative net margin. Investors may look for sustained growth and profitability beyond this quarter. Earnings results

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. The Goldman Sachs Group started coverage on shares of Adaptive Biotechnologies in a research note on Tuesday, September 29th. They set a “buy” rating and a $35.00 target price for the company. National Bank Financial set a $34.00 price target on shares of Adaptive Biotechnologies in a research report on Tuesday, September 22nd. Morgan Stanley lifted their price target on shares of Adaptive Biotechnologies from $22.00 to $27.00 and gave the company an “equal weight” rating in a report on Monday, October 12th. Guggenheim boosted their price objective on shares of Adaptive Biotechnologies from $25.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Finally, TD Cowen increased their price objective on shares of Adaptive Biotechnologies from $28.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Adaptive Biotechnologies presently has a consensus rating of “Moderate Buy” and an average price target of $30.06.

Institutional Trading of Adaptive Biotechnologies

Several hedge funds have recently made changes to their positions in the stock. Nykredit A S bought a new position in Adaptive Biotechnologies during the 2nd quarter worth $31,000. Allworth Financial LP acquired a new stake in Adaptive Biotechnologies in the second quarter worth $35,000. KBC Group NV acquired a new stake in Adaptive Biotechnologies in the first quarter worth $45,000. Integrated Wealth Concepts LLC acquired a new stake in Adaptive Biotechnologies in the second quarter worth $46,000. Finally, Assetmark Inc. lifted its stake in Adaptive Biotechnologies by 46.4% in the first quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock valued at $61,000 after buying an additional 1,401 shares during the last quarter. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.

Adaptive’s products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.